Etrumadenant Boosts Survival in Advanced Colorectal Cancer
Publication Title: The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer.
Summary
- Question
- This study evaluated whether a new combination therapy, called EZFB, improves outcomes for patients with metastatic colorectal cancer (mCRC) who have already been treated with multiple therapies. EZFB combines etrumadenant (an adenosine receptor blocker), zimberelimab (an immune checkpoint inhibitor), chemotherapy (modified FOLFOX-6), and bevacizumab (a drug that targets blood vessel growth). Researchers compared EZFB to regorafenib, a standard treatment for advanced mCRC.
- Why it Matters
- Metastatic colorectal cancer is a leading cause of cancer-related deaths worldwide, and patients who have exhausted standard treatments often face limited options and poor outcomes. Current therapies for refractory mCRC offer modest survival benefits, underscoring the need for innovative approaches. This study is significant because it explores a novel strategy targeting the tumor microenvironment and immune system, which could offer better survival and quality of life for these patients. If successful, the EZFB regimen may provide hope for individuals with advanced colorectal cancer.
- Methods
- The researchers conducted a randomized phase 2 trial involving 112 patients with previously treated mCRC across six countries. Patients were assigned in a 2:1 ratio to receive either EZFB or regorafenib. EZFB included oral etrumadenant, intravenous zimberelimab, chemotherapy (mFOLFOX-6), and bevacizumab. Tumors were monitored every eight weeks, and treatment continued until disease progression or intolerable side effects.
- Key Findings
- Patients treated with EZFB had significantly better outcomes than those receiving regorafenib. Progression-free survival (PFS) was 6.2 months for EZFB versus 2.1 months for regorafenib. Overall survival (OS) was 19.7 months for EZFB compared to 9.5 months for regorafenib. The disease control rate was 63% with EZFB versus 8% with regorafenib. Although side effects were common, they were manageable and mostly related to chemotherapy.
- Implications
- The findings suggest that EZFB could be a promising third-line treatment for metastatic colorectal cancer, offering substantial improvements in survival compared to current options. By targeting adenosine receptors and combining immune-based and chemotherapy approaches, this regimen may enhance anti-tumor activity and reduce immunosuppression in the tumor microenvironment. These results could shift treatment paradigms for advanced colorectal cancer and pave the way for further clinical development.
- Next Steps
- The researchers recommend additional studies to confirm these findings in larger, phase 3 trials. They also suggest exploring biomarkers to identify patients who would benefit most from EZFB and investigating how its components contribute to its effectiveness.
- Funding Information
- This research was supported by Arcus Biosciences, Inc., and Gilead Sciences, Inc. Dr. Cecchini was supported by a National Cancer Institute Mentored Clinical Scientist Research Career Development Award (1K08CA255465-01A1). Medical writing support was funded by Arcus Biosciences and Gilead Sciences. Yale University also provided funding and support for this research.
Full Citation
Cecchini M, Han S, Lee S, Lee K, Kopetz S, Mizrahi J, Hong Y, Ghiringhelli F, Italiano A, Tougeron D, Beagle B, Boakye M, Zhao T, Khemka V, Wainberg Z. The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer. Clinical Cancer Research 2026 PMID: 41870279, DOI: 10.1158/1078-0432.ccr-25-3727.
Authors
Michael Cecchini, MD
First AuthorAssociate Professor of Medicine (Medical Oncology)
Zev A Wainberg
Last Author
Other Authors
Research Themes
Concepts
- Treatment-emergent adverse events;
- Metastatic colorectal cancer;
- Progression-free survival;
- Overall survival;
- Primary endpoint;
- Secondary endpoints;
- Primary endpoints of progression-free survival;
- Secondary endpoint of overall survival;
- Colorectal cancer;
- Endpoint of progression-free survival;
- Confirmed overall response rate;
- Median survival follow-up;
- Endpoint of overall survival;
- Irinotecan-containing regimens;
- Third-line treatment;
- Survival follow-up;
- Overall response rate;
- Clinically Meaningful Improvements;
- Regorafenib arm;
- Adenosine pathway;
- Cohort B;
- Survival outcomes;
- Safety profile;
- Study treatment;
- Adverse events